NEW YORK, NY, September 19, 2013 - (ACCESSWIRE)- IntelliCell Biosciences, Inc. ("Company") (OTC Pink: SVFC) announced today that it has received notification that the Canadian Application, No. 2823123, Entitled: ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USED THEREOF has been filed.
The European Patent EP, Patent Application No. 11854049.1,
Entitled: ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USED THEREOF has also been filed with the EP Communication, and correspondence thereof, advised that they are setting the deadline for February 9, 2014 for voluntary amendment in the above-referenced EP patent application.
Additionally, the Korean patent has been filed as of July 26, 2013, Application No. 10-2013-7020022, Title of Invention: ULTRASONIC CAVITATION STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USED THEREOF. The International Application Number is No.:PCT/US2011/064464.
According to IntelliCell's Chairman and CEO, Steven Victor MD, "This is exciting news for the company in that it now has the ability to legally protect its technology for using ultrasonic cavitation for the manufacturing of stromal vascular fraction containing Mesenchymal Stem Cells from the blood vessels in adipose tissue in numerous countries."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell Biosciences, Inc.
Contact: Anna Rhodes
Email Contact: email@example.com
SOURCE: IntelliCell Biosciences, Inc.
- ADIPOSE TISSUE